Sboll is Your Go-to Source for the Latest Finance News, Covering Markets, Banking, Investments, Economy and Stocks.
⎯ 《 Sboll • Com 》

Rhinostics Launches the ELEstic™/ELEbot™ Platform, Bringing Proven Automated Swab Workflows to Broad Diagnostics Systems

2023-07-25 20:20
WALTHAM, Mass.--(BUSINESS WIRE)--Jul 25, 2023--
Rhinostics Launches the ELEstic™/ELEbot™ Platform, Bringing Proven Automated Swab Workflows to Broad Diagnostics Systems

WALTHAM, Mass.--(BUSINESS WIRE)--Jul 25, 2023--

Rhinostics introduces another breakthrough in automated sample collection technologies with the launch of the patent-pending ELEstic™ swab collection device combined with the groundbreaking ELEbot™ Decapper. The ELEstic includes a high-performance swab attached to a cap that screws into a 75mm by 13mm tube, the diagnostic industry standard that fits into most of the larger closed molecular testing platforms. The ELEbot Decapper provides 24-tube automated decapping of swab samples that can be placed upstream of these molecular testing platforms for sample elution and decapping prior to transferring the sample directly into the diagnostics testing system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725514397/en/

The easy-to-use ELEbot™ Decapper automates decapping and capping of the ELEstic™ swabs from 75mm by 13mm tubes in 24-tube racks. The new system is designed to work upstream of molecular diagnostic analysers from the larger diagnostic manufacturers. The system speeds sample processing and allows more samples to be processed in the same footprint with a smaller staff, in the first completely handsfree swab workflow, lowering dependency on labor and dropping these costs significantly. The ELEstic™ swab employs the proven stacked-ring head, developed at the Wyss Institute, with a successful track record testing millions of COVID-19 patient and medically collected samples. Additionally, laboratories have begun using the swabs for multi-analyte respiratory testing, vaginal and triple-site collection for sexually transmitted infections (STIs), wounds, and other swab sample types. (Photo: Business Wire)

The ELEstic joins the Company’s award-winning platform of proprietary collection devices, including the 96-well RHINOstic®/RHINObot™ system. Both systems integrate a unique, polypropylene swab with an automatable cap. After a patient sample is collected, the swab is placed into a collection tube for dry shipment, bypassing the need for transport media to reduce sample loss during transport and accidental biohazard contact. This feature also enables more rapid and complete elution for increasing sample concentration to drop Limits of Detection (LOD) for many assays; can remove extraction steps; and reduces reagent usage. Both the ELEstic and RHINOstic systems offer significant cost reductions to laboratory workflows through labor and reagent savings.

The easy-to-use ELEbot Decapper automates decapping and capping of the ELEstic in 75mm by 13mm tubes in 24-tube racks. This speeds sample processing and allows more samples to be processed in the same footprint with a smaller staff, in the first completely handsfree swab workflow, lowering dependency on labor and dropping these costs significantly.

The ELEstic employs the proven stacked-ring head, developed at the Wyss Institute, with a successful track record testing millions of COVID-19 patient and medically collected samples. Additionally, laboratories have begun using the swabs for multi-analyte respiratory testing, vaginal and triple-site collection for sexually transmitted infections (STIs), wounds, and other swab sample types.

“We are excited to expand our platform to offer a solution for the closed diagnostic platforms after successfully launching our 96-well solutions for open platforms nearly three years ago. Each lab that adopts our technology quickly realizes the benefits of stream-lined workflows, more reliable and repeatable testing through robotics, reducing labor dependency and costs, and dropping their reagent costs to make a significant impact on their cost of goods. Every laboratory is looking for ways to manage their costs more effectively as reimbursement payments continue to fall,” said Cheri Walker, PhD, President and CEO of Rhinostics.

Rhinostics will mark the global debut of the ELEstic and ELEbot at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo to be held July 25-27 in Anaheim, CA.

About Rhinostics

Rhinostics is at the forefront of revolutionizing sample collection. As a spin-out company from Harvard University and Wyss Institute, we are taking a radical new approach to sample collection device design and function. We recognize that many automated microplate-based workflows are encumbered by manual steps at the workflow’s beginning, and aim to develop and commercialize elegant, automated collection devices to break through these bottlenecks. Using our advanced collection device technologies such as the RHINOstic ® and ELEstic™ Automated Swabs, VERIstic® blood collection devices and HIPPOstic™ DNA collection device, test kit manufacturers can empower comfortable yet high-end patient experiences with abundant and clean sample yields for tests from lateral flow to microfluidics; all while boosting profits and differentiating their brand. Test processing laboratories conducting sensitive assays from traditional PCR to LAMP or antigen testing and more gain increased sample throughput compared to manual workflows for cost-effective and robust assay performance even when working with difficult samples; with labor reductions even during times of surging demand. Rhinostics aids testing workflows in areas including respiratory disease, genomics, STDs, forensic and much more. Rhinostics continues to innovate, launching the three new collection devices and several robotic decapper systems with our partners to provide systems for our purpose-built sample collection devices for their application combined with automation enablement. Rhinostics products are registered as Class I exempt medical devices with the U.S. FDA and may be used for clinical collection upon CLIA validation. To learn more, visit https://www.rhinostics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230725514397/en/

CONTACT: Media and Investor Contact:

Cheri Walker, Rhinostics, Inc.

(877) 746-6789

info@rhinostics.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY HARDWARE HEALTH MEDICAL DEVICES ROBOTICS TECHNOLOGY

SOURCE: Rhinostics

Copyright Business Wire 2023.

PUB: 07/25/2023 08:00 AM/DISC: 07/25/2023 08:01 AM

http://www.businesswire.com/news/home/20230725514397/en